Novavax says its COVID vaccine gets India authorisation for teens


Novavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.

The authorisation is a global first for the age group for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax. 

Novavax last month said its vaccine was 80 per cent effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years. Read full story

The company said on Tuesday its vaccine produced an immune response in the same age group in a mid- to late-stage study involving 460 Indian adolescents.

Covovax is the fourth COVID-19 vaccine to be authorised for adolescents aged 12 years and older in India after Corbevax, ZyCoV-D and Covaxin.

India, which had so far been vaccinating children aged 15 and above, started administering doses of Corbevax last week to children aged 12 to 14. 

The country's drug regulator in December authorised Novavax's COVID-19 vaccine for people aged 18 years and above.

More from International News

On Virgin Radio today

Trending on Virgin Radio

  • See Taylor Swift in London

    See The Eras Tour movie at Roxy Cinemas AND see it in person at Wembley Stadium! Just listen to Virgin Radio (Taylor's Version)

  • Untold Festival

    The biggest performances, interviews and a behind the scenes look before Untold comes to Dubai in February 2024.

  • Mais Vault on the Kris Fade Show!

    The boys tried their 'pick up' lines on Mais Vault and things did not go according to plan...

  • Ed Sheeran - UAE EXCLUSIVE

    Latest album, what happened with BTS, raising a baby girl, eye surgery, and more!